Biotech Values

[Rocky3]

Credit Suisse in one analyst report said the Mayveret gains were predominantly at the cost of Merck - does this tally with the call / anyone else's notes? thanks

In one sense that is true, MRK will lose most of its business, but not all. But it had ~18% of the market when Mayv appeared and GILD had almost 80%. So if MRK ends up with 4% and GILD ends up with ~64% (guesses only), both would have lost 14-16% market share, but it would be ~75% of MRK's market share and 20% of GILD's market share. But both MRK and GILD will lose significantly more revenue that market share loss due to price competition, due to ABBV's pricing. That price loss may be coming to an end, but 4Q17 and 1Q18 will show the effects of the price competition. That is all based on US commercial percentages, but I would expect the same analysis to hold for OUS and US public markets. JMO.